Currently the Enterprise Value (EV) is not available for Y-mAbs Therapeutics.
n/a
n/a
n/a
n/a
Financial Position
The company has a current ratio of 4.16,
with a Debt / Equity ratio of 0.01.
4.16
3.85
0.01
-0.03
-0.05
0
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
n/a
n/a
n/a
$843.13K
$-285.25K
104
0.73
2.11
Taxes
-146K
0.49%
Stock Price Statistics
The stock price has increased by -37.92% in the
last 52 weeks. The beta is 0.53, so Y-mAbs Therapeutics's
price volatility has been higher than the market average.
0.53
-37.92%
6.35
6.18
81.13
911,145
Income Statement
In the last 12 months, Y-mAbs Therapeutics had revenue of 87.69M
and earned -29.67M
in profits. Earnings per share was -0.67.